

66/92/0T



OLD S. N. 01955

TERRELL C. BIRCH  
 RAYMOND C. STEWART  
 JOSEPH A. KOLASCH  
 JAMES M. SLATTERY  
 BERNARD L. SWEENEY\*  
 MICHAEL K. MUTTER  
 CHARLES GORENSTEIN  
 GERALD M. MURPHY, JR.  
 LEONARD R. SVENSSON  
 TERRY L. CLARK  
 ANDREW D. MEIKLE  
 MARC S. WEINER  
 JOE MCKINNEY MUNCY  
 ROBERT J. KENNEY  
 DONALD J. DALEY  
 JOHN W. BAILEY  
 JOHN A. CASTELLANO, III

OF COUNSEL:  
 HERBERT M. BIRCH (1905-1996)  
 ELLIOT A. GOLDBERG\*  
 WILLIAM L. GATES\*  
 EDWARD H. VALANCE  
 RUPERT J. BRADY (RET.)\*

\*ADMITTED TO A BAR OTHER THAN VA

# BIRCH, STEWART, KOLASCH & BIRCH, LLP

INTELLECTUAL PROPERTY LAW  
 8110 GATEHOUSE ROAD  
 SUITE 500 EAST  
 FALLS CHURCH, VA 22042-1210  
 USA

(703) 205-8000

FAX: (703) 205-8050  
 (703) 698-8590 (G IV)

e-mail: mailroom@bskb.com  
 web: http://www.bskb.com

CALIFORNIA OFFICE  
 650 TOWN CENTER DRIVE, SUITE 1120  
 COSTA MESA, CA 92626-7125  
 (714) 708-8555  
 FAX: (714) 708-8565

GARY D. YACURA  
 THOMAS S. AUCHTERLONIE  
 MICHAEL R. CAMMARATA  
 JAMES T. ELLER, JR.  
 SCOTT L. LOWE  
 MARY ANN CAPRIA  
 MARK J. NUEL, PH.D.  
 DARIN E. BARTHOLOMEW\*  
 D. RICHARD ANDERSON  
 PAUL C. LEWIS  
 W. KARL RENNER

REG. PATENT AGENTS:  
 FREDERICK R. HANDREN  
 ANDREW J. TELESZ, JR.  
 MARYANNE LIOTTA, PH.D.  
 MAKI HATSUMI  
 MIKE S. RYU  
 CRAIG A. McROBBIE  
 GARTH M. DAHLEN, PH.D.  
 LAURA C. LUTZ  
 ROBERT E. GOOZNER, PH.D.  
 HYUNG N. SOHN  
 MATTHEW J. LATTIG  
 ALAN PEDERSEN-GILES

Date: October 26, 1999

Docket No.: 1781-178P

JC525 U.S. PRO  
 09/426776  
 10/26/99

## BOX PATENT APPLICATION

Assistant Commissioner for Patents  
 Washington, DC 20231

Sir:

Transmitted herewith for filing is a patent application claiming priority under 35 U.S.C. § 119(e) of Provisional Application No. 60/106,426 filed on October 30, 1998.

Inventor(s): Jeak Ling DING, Nguan Soon TAN, Bow HO, Toong Jin LAM

For: ISOLATED NUCLEIC ACIDS ENCODING A SECRETORY SIGNAL FOR EXPRESSION AND SECRETION OF HETEROLOGOUS RECOMBINANT PROTEINS

Enclosed are:

- ☒ A specification consisting of forty-five (45) pages
- ☒ Twenty-seven (27) sheet(s) of formal drawings
- ☒ An assignment of the invention
- ☐ Certified copy of Priority Document(s)
- ☒ Executed Declaration (☒ Original ☒ Photocopy)
- ☒ A statement (☐ original ☒ photocopy) to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27
- ☐ Preliminary Amendment

- ☐ Information Disclosure Statement, PTO-1449 and reference(s)
- ☐ Other:
- ☒ Amend the specification by inserting before the first line the sentence:

--This application claims priority on provisional Application No. 60/106,426 filed on October 30, 1998, the entire contents of which are hereby incorporated by reference.--

The filing fee has been calculated as shown below:

			LARGE ENTITY	SMALL ENTITY
BASIC FEE			\$760.00	\$380.00
	NUMBER FILED	NUMBER EXTRA	RATE FEE	RATE FEE
<b>TOTAL CLAIMS</b>	68- 20 =	48	X 18 = \$0.00	x 9 = \$432.00
<b>INDEPENDENT CLAIMS</b>	7- 3 =	4	x 78 = \$0.00	x39 = \$156.00
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED			+ \$260.00	+ \$130.00
<b>TOTAL</b>			\$0.00	\$1,098.00

- ☒ A check in the amount of \$1,138.00 to cover the filing fee and Assignment recordation fee is enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. A triplicate copy of this transmittal form is enclosed.
- ☒ Please send correspondence to:

BIRCH, STEWART, KOLASCH & BIRCH, LLP or Customer No. 2292  
P.O. Box 747  
Falls Church, VA 22040-0747  
Telephone: (703) 205-8000

Docket No. 1781-178P

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #3288

Gerald M. Murphy, Jr., #28,977

GMM/DRN/las  
1781-178P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachments

(Rev. 09/15/99)

**STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(d)) - NONPROFIT ORGANIZATION**Docket Number: 1781-178PApplicant, Patentee, or Identifier: Jeak Ling DING et al.

Application or Patent No.: \_\_\_\_\_

Filed or Issued: \_\_\_\_\_

Title: ISOLATED NUCLEIC ACIDS ENCODING A SECRETORY SIGNAL FOR EXPRESSION AND SECRETION OF  
HETEROLOGOUS RECOMBINANT PROTEINS

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION

National University of Singapore

ADDRESS OF NONPROFIT ORGANIZATION

10 Kent Ridge Crescent, Singapore 119260

## TYPE OF NONPROFIT ORGANIZATION:

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION  
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. 501(a) and 501(c)(3))  
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA  
(NAME OF STATE \_\_\_\_\_)  
(CITATION OF STATUTE \_\_\_\_\_)  
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. 501(a) and 501(c)(3)) IF  
LOCATED IN THE UNITED STATES OF AMERICA  
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED  
STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA  
(NAME OF STATE \_\_\_\_\_)  
(CITATION OF STATUTE \_\_\_\_\_)

I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☒ the specification filed herewith with title as listed above.  
☐ the application identified above.  
☐ the patent identified above

I hereby state that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above-identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities and that no rights in the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

- Each person, concern, or organization having any rights in the inventions is listed below:  
☒ no such person, concern, or organization exists.  
☐ each such person, concern, or organization is listed below.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING \_\_\_\_\_

TITLE IN ORGANIZATION OF PERSON SIGNING \_\_\_\_\_

ADDRESS OF PERSON SIGNING National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260

SIGNATURE \_\_\_\_\_

DATE

25 October 1999

Rev. 10/12/1998

**CHOU Siaw Kiang (Dr)**

Director

Industry &amp; Technology Relations Office (INTRO)

National University of Singapore

**ISOLATED NUCLEIC ACIDS ENCODING A SECRETORY SIGNAL FOR  
EXPRESSION AND SECRETION OF HETEROLOGOUS RECOMBINANT PROTEINS**

**FIELD OF THE INVENTION**

The present invention relates to the use of nucleic  
5 acids (termed "SS" for "secretory signal" or "Vtgss" for  
"vitellogenin secretory signal") that function as universal  
secretory signals for rapidly directing recombinant proteins  
out of a heterologous host cell. The invention is also  
applicable to improved and more convenient means of  
10 detecting reporter proteins by simply sampling culture  
medium in which cells harboring constructs of the invention  
are maintained. The invention is also applicable to  
biosensor technology, to for screening of genetically-  
engineered clones harboring selectable marker(s) to be  
15 expressed as an indicator, and to achieving systemic  
circulation/distribution of recombinant proteins in a  
transgenic or chimeric host organism.

**DESCRIPTION OF THE RELATED ART**

Although protein expression in bacteria is commonly  
20 used to obtain recombinant proteins, bacterial hosts present  
several drawbacks to expression of recombinant proteins.  
First, eukaryotic proteins expressed in *E. coli* are often  
not properly folded and thus non-functional (Cleland, J. L.  
1993, *In Protein Folding In Vivo and In Vitro*: pp. 1-21).  
25 This is a large problem, since most proteins used for  
pharmaceutical/diagnostic purposes are eukaryotic in nature.  
Second, proteins expressed in large amounts in *E. coli* often  
precipitate into insoluble aggregates called "inclusion  
bodies", from which they can only be recovered in an active  
30 form by solubilization in denaturing agents followed by

careful renaturation (Chang and Swartz, 1993, in "Protein Folding *In Vivo* and *In Vitro*", Cleland, J. L. ed., pp. 178-188). Third, it is difficult to engineer the secretion of large amounts of expressed protein in *E. coli*, although it has often been possible to secrete small amounts into the periplasmic space and to recover them by osmotic shock. Finally, the recovered recombinant protein is usually contaminated with an unacceptable level of endotoxin/pyrogen that makes proteins for pharmaceutical/diagnostic use extremely difficult to validate (Walsh and Headon, 1994, in "Protein Biotechnology", pp. 118-162).

Although, protein expression in yeast (*Saccharomyces cerevisiae*) can solve some of the problems associated with bacterial expression, the harsh conditions necessary to lyse the yeast often result in poor yield and denaturation of the recombinant proteins. Secretion of recombinant proteins from yeast has largely been a trial and error effort. Furthermore, most secreted proteins are trapped in the yeast periplasmic space and thus, difficult to retrieve (Lemontt et al., *DNA* 4:419-428 (1985); Martegani et al., *Appl. Microbiol. Biotechnol.* 37:604-608 (1992)).

The mammalian and insect expression systems have a number of advantages that have contributed to the recent popularity (Straten et al., 1989, in "Invertebrate Cell Systems Applications", pp. 183-193; Yarranton, G. T., *Curr. Opinion Biotech.* 1:133-140 (1990)). Recombinant proteins are almost always expressed at high levels and the expressed proteins are usually properly modified and accumulated in the proper cellular compartment. However, there have been occasions where the use of the homologous secretory signal of the gene insert resulted in mistargetting of the expressed proteins, which consequently remained within the

yeast. Generally, protein expression in higher eukaryotes such as insect cells and mammalian cells is challenging, time-consuming and expensive although they are suitable hosts for small- and medium-scale work.

5       An example of a *Drosophila* expression system utilizes a cell line derived from *Drosophila melanogaster*, Schneider 2 (S2) cells, and a simple plasmid vector for the expression of heterologous proteins (Ivey-Hoyle, M., *Curr. Biol.* 2:704-707 (1991)). S2 cells and mammalian cells such as CHO cells  
10 have been used to express proteins for both biochemical assays and therapeutics. In both the insect and mammalian cell systems, there is a therefore a need to employ powerful secretory signals to drive the secretion of the expressed recombinant proteins out of the heterologous host cells for  
15 easy detection, quantification and large-scale purification.

For an efficient expression system, several criteria need to be satisfied. First, the recombinant protein synthesis must be functional. Second, a reasonable yield of the protein is required to justify its usage. Third, the  
20 system must enable homogenous synthesis of the recombinant protein. Last, the system should allow easy scaling-up and subsequent downstream processing, for example, purification. Consequently, we have constructed recombinant fusion vectors that direct the secretion of heterologous proteins into the  
25 medium used to culture various host cells.

An important aspect of the study of gene regulation is assay of transcription levels observed from wild-type and mutant versions of putative *cis*-acting control elements in transfected mammalian cells. In most cases, the ability of  
30 the *cis*-acting elements to modulate transcription is not assayed directly. Instead, the *cis*-acting elements are joined to a reporter gene that codes for a measurable enzyme

activity. The level of the enzymatic activity that accumulates during the course of an experiment is taken as a measure of the ability of the *cis*-acting element to regulate transcription. Although this is an indirect assay of the activity of the *cis*-acting elements that control transcription, it is often the only one that is practicable. A number of different genes have been used as reporters of the transcriptional activity of eukaryotic promoters. These include chloramphenicol acetyltransferase (CAT),  $\beta$ -galactosidase and luciferase. However, all these require lysis of the transfected cells and thus are subject to the problems associated with set-up and variability of multiple cultures.

To date, the Great ESCAPE SEAP Genetic Reporter System<sup>TM</sup> (Clontech) is one available system that utilizes a secreted form of an enzyme, human placental alkaline phosphatase, as a reporter for the analysis of *cis*-acting DNA sequences and *trans*-acting factors. However, a drawback of the SEAP assay is that it has to be measured using either a fluorescent or chemiluminescent assay, requiring a fluorimeter or a luminometer. Furthermore, it requires the investigator to switch from their established protocols for CAT,  $\beta$ -galactosidase or luciferase.

#### **SUMMARY OF THE INVENTION**

The present invention stems from the finding that the secretory signal sequence (SS or Vtgss) of the vitellogenin gene, especially the vitellogenin gene from *Oreochromis aureus*, can be used to direct the secretion of recombinant proteins out of cells. The cells that are able to utilize the *O. aureus* SS are not particularly limited; the present inventors have found that cells of many kinds, especially



eukaryotic cells, will efficiently process exogenous fusion proteins comprising the SS of the invention and secrete them from the cell.

Thus, one aspect of the present invention is isolated  
5 nucleic acids that encode a SS that provides the biological activities of directing secretion of a protein linked to the SS from a host cell and cleavage of the SS from the fusion protein at a particular point in the SS sequence. The isolated nucleic acids of the invention are easily  
10 incorporated into vectors for expression of recombinant proteins and subsequent secretion of the fusion protein, processed by appropriate cleavage of the SS portion, into the medium used to culture the host cells. An advantage of the present invention is that the secretion is very  
15 efficient regardless of the particular protein secreted or the host cell used to express the recombinant protein.

Thus, the present invention resides in part in the development of an efficient and versatile vector for high level expression and immediate secretion of recombinant  
20 proteins into serum-free medium used to culture the host cells. The host cells can be immobilized, or else easily removed from the culture, thus providing easy purification of the recombinant proteins. Also, vectors comprising the SS of the invention and a reporter gene will express and  
25 efficiently secrete the reporter proteins, thus enabling easy detection of the reporter protein, for example by sampling of the culture medium, or of an extracellular fluid in the instance of an *in vivo* assay.

As a result of the efficient processing conferred by SS  
30 of the present invention, the invention provides assays of gene expression levels by measuring the amount of a reporter gene that is secreted into medium used to culture cells

harboring vectors of the invention. An advantage of such an assay is that cells expressing the reporter gene need not be lysed to perform the assay, allowing the assay to be used for screening of clones for expression of recombinant  
5 constructs or that are co-transformed with additional vectors.

The invention also encompasses biosensors comprising cells that are transformed with vectors according to the present invention. Such biosensors can be applied to  
10 detection of compounds present in samples by addition of the samples to media used to culture cells of the invention, followed by measurement of the activity of reporter proteins in the culture media whose expression is induced or repressed by the introduction of the compound into the  
15 medium.

The present invention can also be applied to the expression of desired proteins in transgenic or chimeric organisms *in vivo*. In some instances, it is desirable to obtain secretion of a protein into the extracellular spaces  
20 in an organism, including extracellular matrix, various secretory ducts, peritoneal fluid, ventricular fluid, the bloodstream or the lymphatic system. The present invention can be applied to directing secretion of a desired protein into any of these extracellular spaces.

25 Control of expression of a desired gene, followed by secretion of the gene product from the cell, for example in a tissue-specific manner, or in a manner inducible by treatment with a particular chemical compound, can be achieved by linkage of an appropriate promoter to a  
30 structural gene comprising nucleotides encoding the SS of the invention linked to a nucleotide sequence encoding the desired gene product.

# **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows the construction of pAc5/VtgCrFCES-V5-His. The full-length CrFC21 cDNA encoding Factor C was released by a Bgl II and Not I double digest. The released  
5 fragment was subcloned into the Bam HI and Not I sites of VtgEGFP. Consequently, the Bgl II/Bam HI site is destroyed. Then the LPS-binding domain of CrFC21 was released by digestion with Eco47 III and Sal I (cutting an internal site). The fragment was subcloned into the Eco RV and Xho I  
10 sites of pAc5/V5-HisA to give pAc5/VtgCrFCES-V5-His. Both Eco47 III/Eco RV and Sal I/Xho I sites are destroyed.

Figure 2A shows the amino acid and nucleotide sequences at the junction of Vtgss and CrFCES. The nucleotide  
15 junctions were determined by sequencing using the Ac5 forward primer and pcDNA3.1/BGH reverse primer. The CrFCES is cloned in-frame with respect to Vtgss (at the 5' end) and V5-His (at the 3' end). The secreted VtgCrFCES protein was purified by affinity chromatography (TALON™, Clontech) under denaturing conditions (6M urea, 250 mM NaCl and 20 mM sodium  
20 phosphate buffer, pH7.0). The protein was transferred to a PVDF membrane in transfer buffer (10 % methanol, 10 mM CAPS, pH 11.0) and its N-terminal amino acid sequence determined. Using the novel Vtgss as secretory signal, only a single cleavage point was identified (indicated by the arrow).  
25 Thus, Vtgss allows the homogenous production of secreted heterologous recombinant protein.

Figure 2B shows a map of the plasmid pAc5/VtgCrFCES-V5-His.

Figures 3A and 3B show the distribution of secreted  
30 VtgCrFCES protein.

Figure 3A - culture medium

Lane M: Benchmark™ prestained marker

Lane 1: control medium (30 µg)  
Lane 2: VtgCrFCES medium (not purified 30 µg)  
Lane 3: VtgCrFCES (affinity purified; 1 µg)  
Lane 4: VtgCrFCES (ISOpri<sup>TM</sup> purified; 1 µg)

5        Figure 3B - cell lysate;

Lane M: Bio-Rad prestained marker  
Lane 1: control cell lysate (30 µg)  
Lane 2: VtgCrFCES cell lysate (transient; 30 µg)  
Lane 3: VtgCrFCES cell lysate (stable; 30 µg)

10        The VtgCrFCES (hereinafter "VtgCrFCES") protein was  
effectively secreted into the culture medium, as verified by  
SuperSignal HisProbe<sup>TM</sup> Western Blotting Kit (Pierce). The  
secreted VtgCrFCES was purified to homogeneity by  
isoelectric focusing (ISOpri<sup>TM</sup>, Hoefer) resulting in a  
15        single protein band having a molecular weight identical to  
that of the protein isolated by affinity column  
chromatography. The ISOpri<sup>TM</sup>-purified protein was not  
denatured even when purified in pyrogen-free water. No  
VtgCrFCES was detected in the cell lysate. The purification  
20        process was made easy and more effective by the presence of  
VtgCrFCES in the culture medium.

Figure 4 shows the lipid A binding properties of  
ISOpri<sup>TM</sup>-purified VtgCrFCES. Immobilization of lipid A to  
the HPA sensor chip has been described earlier (Pui et al.,  
25        *J. Endotoxin Research* 4:391-400 (1997)).

Injection of VtgCrFCES (800ng/100µl) resulted in a  
signal of ~2000 relative response units. This represents a  
~92% saturation of lipid A which clearly indicates that  
VtgCrFCES binds to lipid A. Subsequently, injection of  
30        antibody (INDIA His-HRP Ab) against the poly-His tag of  
VtgCrFCES resulted in a further increase in the signal. The  
binding of INDIA His-HRP Ab further confirms that only

VtgCrFCES was bound to the immobilized lipid A. The result also indicates that the six additional Vtgss-derived amino acids in the N-terminus of the protein do not interfere with the proper folding of the recombinant protein and its LPS-binding property. The properly folded VtgCrFCES is secreted. Injections of samples at various steps are marked on the sensogram. "Wash" indicates a washing step using pyrogen-free water. The relative response units of the signal are obtained by subtracting the response units recorded just before injection of sample from the response units recorded after injection of sample and a 2 min wash.

Figure 5A shows the construction of psp-VtgCAT. The CAT gene was isolated by PCR. The start ATG codon of the CAT gene was changed to CTG to ensure translation initiation at Vtgss as indicated in bold in the sequence of the CAT forward primer (5'-GAA GAT **CTG** CTG GAG AAA AAA ATC ACT GG-3'). The stop codon of the CAT gene is indicated in bold in the CAT reverse primer (5'-GC ATC GGC CGT GCC TTA AAA AAA **TTA** CGC-3'). The temperature profile used includes a 1<sup>st</sup> cycle (94 °C/5 min; 50 °C/1 min; 72 °C/1 min), 29 cycles (94 °C/45 sec; 50 °C/30 sec; 72 °C/30 sec) and final extension at 72 °C for 5 min. The PCR product of ~675 bp was purified using a Qiaquick<sup>TM</sup> PCR Purification Kit and subcloned into the Hinc II site of pBluescript<sup>TM</sup> II SK. The resultant construct is named pBSCAT. The CAT gene was released by Bgl II and Not I digestion and subcloned into compatible Bam HI and Not I sites of pVtgEGFP. The CAT gene harboring Vtgss (VtgCAT) was subsequently released by using Eco47 III and Not I digest and recloned into the Eco RV and Not I sites of pBluescript<sup>TM</sup> II SK to form the vector pBSVtgCAT. This recloning step serves two purposes: (1) the sequences between Vtgss and CAT can be determined using a T7 primer;

(2) this creates a Hind III site 5' of VtgCAT and a Cla I site 3' of VtgCAT for future subcloning into the pSEAP-Promoter vector.

Figure 5B shows the details of the Vtgss-CAT fusion in the pBSVtgCAT vector.

Figure 5C shows the plasmid map of the pSEAP-Promoter vector.

Figure 5D shows the amino acid and nucleotide sequences adjoining Vtgss and CAT in the vector psp-VtgCAT. The sequences between Vtgss and CAT were verified by Taqtrack<sup>TM</sup> sequencing (Promega) using a T7 primer. Both EcoRV/Eco47 III and Bgl II/Bam HI sites were destroyed.

Figure 5E shows the detailed plasmid map of psp-VtgCAT. The VtgCAT gene was subcloned downstream of the SV40 early promoter. The unique restriction enzymes in the multiple cloning site (MCS) were as illustrated. This construct can be used to analyze enhancer sequences cloned into any one of the unique sites in the vector.

Figure 5F shows the plasmid map of ERU-*psp*-VtgCAT. The estrogen response unit (ERU) of 565 bp from the *Xenopus* vitellogenin B1 gene was subcloned into the Nhe I and Bgl II site of *psp*-VtgCAT. The Nhe I/Xba I site was destroyed. The transcription of VtgCAT is under the influence of estrogen in this construct.

Figure 5G shows restriction digests of various constructs.

Lane 1: 100 bp marker

Lane 2: ERU-*psp*-VtgCAT/Hind III and Cla I

Lane 3: *psp*-VtgCAT/Hind III and Cla I

Lane 4: pSEAP-Promoter/Hind III and Cla I

Lane 5: cER in pSG1/Hind III

The VtgCAT (~830 bp) fragment can be released by Hind III and Cla digestion.

The upper band for ERU-psp VtgCAT is slightly larger than psp-VtgCAT because it contains a ~560 bp ERU.

5 Figure 6 shows the secreted VtgCAT expression profile over time in COS-1 cells. The COS-1 cells were cotransfected with ERU-psp-VtgCAT, pSG cER (chicken estrogen receptor expression vector) and pSEAP-Control in a ratio of 6:3:1. The result illustrates several important features. First, 10 the recombinant VtgCAT was effectively secreted and accumulated in the culture medium. Second, the secretion of VtgCAT was not delayed. The uninduced cells (open box) exhibited only a marginal increase in VtgCAT over the period of 24 h. For induced cells (solid box), the increase in the 15 production and secretion of VtgCAT can be detected as early as 2 h after the E<sub>2</sub>-induction. A peak 7-fold increase (~1400 µg VtgCAT/U SEAP activity/h) in VtgCAT was observed 12 h post-induction as compared to the corresponding control. By 24 h, the VtgCAT decreased to ~1000 µg VtgCAT/U SEAP 20 activity/h. The secreted VtgCAT was assayed using CAT ELISA (Boehringer Mannheim) SEAP was measured as described in Tan et al., *Mol. Cell. Endocrinol.* 123:146-161 (1996)). The VtgCAT amount was normalized using SEAP activity. 1x10<sup>-8</sup> M or estradiol was used for induction in all experiments.

25 Figure 7 shows a Northern blot analysis of E<sub>2</sub>-induced VtgCAT expression for ERU-psp-VtgCAT. Total RNA was isolated from the COS-1 cells for E<sub>2</sub>-induced and uninduced cells using RNAeasy<sup>TM</sup> Mini Kit (Qiagen). Ten µg of RNA was resolved on a 1.2 % formaldehyde/agarose gel and alkaline transferred onto 30 Hybond-N<sup>+</sup><sup>TM</sup> membrane (Amersham). The membrane was probed initially with VtgCAT, stripped and reprobed with a mouse actin gene. The result indicates that the levels of VtgCAT

in the culture medium are directly proportional to changes in intracellular concentration of VtgCAT mRNA. Thus, Vtgss can be utilized for reporter gene studies since there is no delay in its production and secretion. An actin cDNA probe

5 was used to normalize the result.

Lane 1: 0 h

Lane 2: 2 h

Lane 3: 4 h

Lane 4: 6 h

10 Lane 5: 12 h

Lane 6: 24 h

Figure 8A shows the construction of pVtgEGFP. The Vtgss was isolated by PCR using a vector T3 primer and a OaVtgExon2 reverse primer (5'-CCAAGTTGGACTGGTCCCCCA-3')

15 using pOaVtg 1 as a template. The PCR conditions used includes a 1<sup>st</sup> cycle (94 °C/5min; 52 °C/1 min; 72 °C/1 min), 29 cycles (94 °C/1min; 52 °C/30 sec; 72 °C/30 sec) and final extension of 72 °C 5 min. The PCR product was purified using Qiaquick<sup>TM</sup> Nucleotide Purification Kit (Qiagen) and digested

20 with Sac I. This blunt-end (from the PCR) and Sac I fragment was subcloned into the Sma I and Sac I sites of pEGFP-N1 (Clontech). Consequently, the Sma I site of pEGFP-N1 was destroyed. To reduce the distance between the transcriptional start site and the promoter, the clone was

25 digested with Eco RI and Bgl II, Klenow end-filled, and religated to give pVtgEGFP.

Figure 8B shows the details of the Vtg-EGFP fusion in the vector pVtgEGFP.

Figure 8C shows the detailed plasmid map of pVtgEGFP.

30 The VtgEGFP was subcloned downstream of the CMV promoter. Several unique sites flank both the Vtgss and EGFP to allow more flexibility in cloning. The sequence junction of Vtgss



EGFP was determined using Tagtrack<sup>TM</sup> sequencing and an EGFP reverse primer (5'-CCCTCGCCGGACACGCTGA-3'). The transcriptional start site was determined by Teo et al. ("A Novel Piscine Vitellogenin Gene: Structural and Functional Analyses of Estrogen-Inducible Promoter", *J. Mol. Cell. Endocrin.* (1998), in press).

Figure 8D shows western blot analysis of VtgEGFP expression in COS-1 cells. Transient transfection of COS-1 cells with pVtgEGFP was performed using Lipofectamine<sup>TM</sup> (Gibco). Forty-eight hours post transfection, both the medium and cell lysate were sampled. The result indicates that majority of VtgEGFP was secreted into the culture medium. A weaker immunoreactive band was also identified in the cell lysate using GFP antibodies. This is most likely due to the translation initiation at the start ATG codon of native EGFP. This shows that Vtgss can direct secretion of another reporter gene, EGFP. However, the optimal result for Vtgss-directed secretion can be achieved if the start codon of the EGFP gene is replaced or removed so that translation begins at the start codon of the Vtgss.

Lane M: Bio-Rad Kaleidoscope<sup>TM</sup> marker

Lane 1: control culture medium (24 h, 30 µg)

Lane 2: VtgEGFP culture medium (24 h, 30 µg)

Lane 3: VtgEGFP culture medium (48 h, 30 µg)

Figure 9 shows the secreted VtgCAT expression profile over time in NIH/3T3 (normal mouse fibroblast) and CHO-B (Chinese hamster ovary) cells. NIH/3T3 and CHO-B cells were cotransfected with ERU-psp-VtgCAT, pSG cER (chicken estrogen receptor expression vector) and pSEAP-Control in a ratio of 6:3:1 using Lipofectamine<sup>TM</sup> (Gibco). The result shows that recombinant VtgCAT was effectively secreted and accumulated in the culture medium. Thus, secretion of VtgCAT was not

limited to COS-1 cells; estrogen-induced expression of ERU-  
psp-VtgCAT can also be observed in other mammalian cells.  
The uninduced cells (open box) exhibited only a marginal  
increase in VtgCAT over the period of 24 h. For induced  
5 cells (solid box), the increase in the production and  
secretion of VtgCAT can be detected in the earliest  
indicated time point of 6 h after the E<sub>2</sub>-induction. A peak  
showing 4-fold (~400 µg VtgCAT/U SEAP activity/h) and 5.5-  
fold (~550 µg VtgCAT/U SEAP activity/h) increase in VtgCAT  
10 were observed for NIH/3T3 and CHO-B cells, respectively. In  
contrast to COS-1, the lower level of induction is due to  
the lack of the large T-antigen which would otherwise  
amplify the signal. Importantly, the results indicate that  
the secretion of VtgCAT is not limited to a particular cell  
15 type. The secreted VtgCAT was assayed using CAT ELISA  
(Boehringer Mannheim). SEAP was measured as described by Tan  
et al. *Mol. Cell. Endocrinol.* 123:146-161 (1996)). The  
VtgCAT amount was normalized using SEAP activity.

Figure 10 shows the secreted VtgCAT expression profile  
20 over time in EPC (carp epithelial cells), a piscine cell  
line. (Open box, uninduced; solid box, estrogen-induced  
cultures.) A detectable amount of VtgCAT can be observed at  
6 h. The EPC cells were cultured at a low temperature of 25  
°C. A 3-fold increase in VtgCAT can be detected by 24 h after  
25 estrogen-induction. The efficient production and secretion  
of VtgCAT was again demonstrated in this piscine cell line.  
The low metabolic rate of EPC would conceivably produce less  
VtgCAT, but this does not affect the secretion efficiency  
conferred by the SS of the invention. The secreted VtgCAT  
30 was assayed using CAT ELISA (Boehringer Mannheim). SEAP was  
measured as described in Tan et al., *Mol. Cell. Endocrinol.*,

123:146-161 (1996)). The VtgCAT amount was normalized using SEAP activity.

Figure 11 shows the construction of pYEX-VtgCAT. The pYEX-VtgCAT vector basically used the backbone from pYEX-S1 (Clontech) except that the original *K. lactis* killer toxin signal sequence was replaced by Vtgss. Due to the limited number of cloning sites in the original pYEX-S1, an intermediate vector pBSPGK was constructed. pBSPGK consists of the PGK promoter, released via Hind III and Eco RI digestion from pYEX-S1, and subcloned into the corresponding sites of pBluescript<sup>TM</sup> II SK. This construct is a very useful intermediate as it provides more unique sites for cloning genes of interest. The VtgCAT fragment was released from pVtgCAT by Eco47 III and Eag I digestion and subcloned into the Sma I and Eag I sites of pBSPGK, respectively. The entire fragment harboring the PGK promoter and VtgCAT was released by Hind III and Sac I digestion and subcloned into the similar site of pYEX-S1. Consequently, expression of pYEX-VtgCAT was driven by the strong constitutive PGK promoter and transcription terminated by the PGK terminator.

Figure 12 shows the expression profile of VtgCAT in two different yeast transformants over 72 hours. The construct pYEX-VtgCAT was transformed into *S. cerevisiae* strain DY150 using the single-step transformation method described by Chen et al., *Curr. Genet.* 21:83-84 (1992)). The transformants were selected on synthetic minimal medium agar containing all the required supplements except uracil. 100 ml YEPD medium (pH 5.0) contained in a 500 ml baffled flask was inoculated with a single colony of pYEX-VtgCAT and grown for 16 h at 30 °C with vigorous shaking. Subsequently, 2 X 50 ml of the yeast were collected independently by centrifugation for 10 min at 800 x g. One 50 ml pellet was

resuspended in 200 ml YEPD medium and grown for 72 h at 30 °C with vigorous shaking in a 1 L baffled flask. The other 50 ml pellet was resuspended in 200 ml minimal medium (MM) and grown as above. At 24, 48, and 72 h, two ml aliquots of the culture were removed. The yeast and medium were separated by centrifugation. The cell lysate was obtained by lysing the yeast pellet (resuspended in phosphate buffered saline) with glass beads, while the culture medium was collected and frozen without any pre-treatment. The pH of the culture was also monitored using appropriate universal pH indicator paper and adjusted to pH 5.0 using 1 M potassium phosphate buffer (pH 8.0). The amount of VtgCAT secreted into the culture medium and in the cell lysate were assayed using CAT ELISA (Boehringer Mannheim). Total soluble protein was used to normalize the data.

Figure 13 shows the construction of pBADVtgblactKana. The  $\beta$ -lactamase gene was isolated by PCR using blactfor (5'-CCGGGATCCAGAAACGCTGGTGAAAGTAA-3') and blactrev primers (5'-GCGGCCGTTACCAATGCTTAATCAGTGAG-3') using pBluescript<sup>TM</sup> II SK as a template. The PCR primers were designed to exclude the native  $\beta$ -lactamase secretory signal. The PCR conditions used include a first cycle (94°C/45 sec; 50°C/30 sec; 72°C/1 min), 29 cycles (94°C/45 sec; 50°C/1 min; 72°C/30 sec) and final extension (72°C/5 min). The approximately 790 basepair PCR product was purified using a Qiaquick<sup>TM</sup> PCR Purification Kit (Qiagen) and digested with Bam HI and Eag I. This BamHI-EagI PCR fragment was subcloned into the BamHI and Not I sites of pVtgEGFP. To maintain optimal distance between the promoter and the ATG start codon, a second round of PCR was performed using BspSSFor (5'-GGGTCATGAGGGTGCTTGTACTAGCTCTT-3') and blactrev primers and using pVtgblact as template. The second PCR follows a thermal regime of a first cycle

-17-

(94°C/5 min; 60°C/1 min; 72°C/1 min), 29 cycles (94°C/45 sec; 60°C/30 sec; 72°C/30 sec) and a final extension of 72°C/5 min. The resulting PCR fragment of about 865 basepairs was purified as above and cloned into Bluescript™ II SK. This Vtg-β-lactamase fragment was released by BspHI and EcoRI digestion and subsequently subcloned into the NcoI and EcoRI sites of pBAD/myc-His B. The vector's β-lactamase gene was released by BspHI digestion, and the vector ends were blunt-ended by Klenow enzyme. Then a kanamycin resistance gene obtained as a 2461 basepair Dra I fragment from pGFP-N3 was inserted into the blunt-ended vector. The resulting plasmid, named pBADVtgblactKana was transformed into *E. coli*. LM194 competent cells.

Figure 14A shows the amino acid and nucleotide sequences at the junction of Vtgss and β-lactamase in pBADVtgblactKana.

Figure 14B shows the plasmid map of pBADVtgblactKana. The Vtg-β-lactamase gene was cloned downstream of the araBAD promoter (pBAD). The translation initiation site of Vtgss was constructed so that it is 9 basepairs from the optimized ribosome-binding site. The sequence junction of Vtg-β-lactamase was determined using Taqtrack™ sequencing. Both the BspHI site of Vtg-β-lactamase and Nco I site of the pBAD/myc-His B vector were destroyed.

Figure 15 shows a plating assay of Vtg-β-lactamase induction. In the absence of inducer or at very low levels of inducer (arabinose), no colonies are observed. Increasing amounts of inducer provides for survival of increasing numbers of colonies. Thus, when a selectable marker gene is used as a reporter gene, the plating assay provides an easy semi-quantitative assay for reporter gene activity.

Figure 16 shows the growth profile of the bacteria after induction with arabinose. The growth profile was monitored at O.D.<sub>600nm</sub>. It is clear from the graph that a pBADVtgblactKana clone grown in RM medium (■) with 0.2% glucose (i.e., no induction) exhibited a growth profile similar to the control LM194 host bacteria (●). Addition of arabinose, at various concentrations, affected the growth of the pBADVtgblactKana clone. Best growth is seen only when 0.0002% arabinose was used (▲). Higher concentrations of arabinose ( $\geq 0.02\%$ ) resulted in a decrease in cell density. This is probably due to either (1) compromised growth of the cells due to overexpression of Vtg- $\beta$ -lactamase or (2) toxicity due to a high level of Vtg- $\beta$ -lactamase activity. The decrease in cell density has a pronounced effect on secretion of Btg- $\beta$ -lactamase. The induction procedure was as described by the manufacturer (InVitrogen).

Figure 17 shows the expression profile of Vtg- $\beta$ -lactamase in the periplasmic space of bacteria. From the graph, no Vtg- $\beta$ -lactamase was produced when a pBADVtgblactKana clone was cultured in RM medium with 0.2% glucose (●). This is expected since no inducer is added. Addition of arabinose resulted in expression and accumulation of Vtg- $\beta$ -lactamase in the periplasmic space. The early expression profile is dose-dependent, with the highest expression observed when 0.2% arabinose was used (◆). However, by 4 h, this dose-dependent profile is not observed. This could be directly due to the growth retardation as seen in Figure 15. Importantly, the recombinant Vtg- $\beta$ -lactamase is functional and exhibited properties similar to native  $\beta$ -lactamase when measured using the standard colorimetric assay for  $\beta$ -lactamase (Cohenford et al., *Anal. Biochem.*, 168, 252-258 (1988)). The

periplasmic space fraction was isolated as described by Laforet and Kendall (*J. Biol. Chem.*, 266, 1326-1334 (1991)). The values obtained from the various time points for pBADVtgblactKana were subtracted from those of the  
5 corresponding LM194 controls.

Figure 18 shows the expression profile of Vtg- $\beta$ -lactamase in culture medium. From the graph, no Vtg- $\beta$ -lactamase can be detected when a pBADVtgblactKana clone was grown in 0.2% glucose (•). Again, this is expected since no  
10 inducer is present. Surprisingly, Vtg- $\beta$ -lactamase was detected in the culture medium, although not at as high a level as in the periplasmic space. But Vtg- $\beta$ -lactamase in the culture medium was measured in the dilute medium. Even more surprising is that the Vtg- $\beta$ -lactamase expression  
15 profile is reversed as compared with the Vtg- $\beta$ -lactamase accumulation in the periplasm. The highest concentration of Vtg- $\beta$ -lactamase was detected in the medium when the lowest concentration of 0.0002% arabinose was used in the culturing (■). Obviously, the ratio of induction and growth profile of  
20 bacteria are important factors. Rapid and high accumulation of Vtg- $\beta$ -lactamase in the periplasmic space does not translate into efficient secretion into the medium. Instead, low-level induction is preferred. The medium was clarified of bacteria by centrifugation at 4°C for 10 min at 12,000  
25 xg. The filtered medium was kept in ice until all the samples were collected for assay.

Figure 19 shows the cloning strategy of pVtg-Gal. The  $\beta$ -galactosidase coding sequences was PCR amplified using ForBamGal (5'-CCATGGATCCCGTGATTTCGTTGCCGGTCT-3') and  
30 RevEagGal (5'-GCGACGGCCGGGCAGACATGGCCTGC-3') using p $\beta$ gal-promoter (Clontech) as template. The PCR product was digest with Ban HI and Eag I and ligated into similar sites in

pVtgblact. Using pBluescript II SK as an intermediate vector, a ~1.3 kb fragment harboring Vtgss and the 5' coding region of  $\beta$ -galactosidase was subcloned into p $\beta$ gal-promoter at the Hind III and Eco RV sites. This vector expressing  
5 secreted  $\beta$ -galactosidase was designated pVtg-Gal.

Figure 20 shows western blot analysis of Vtg-Gal using mouse anti- $\beta$ -galactosidase. Fifty ug of medium was loaded and electrophoresed on a 10% SDS-PAGE gel. Lane 1: Day 5 medium; Lane 2: Day 4 medium; Lane 3: Day 3 medium; Lane  
10 4: Day 2 medium; Lane 5: control medium; Lane 6: Blank; Lane 7: 20 ug of cell lysate from day 5 culture. The western blot was developed using Goat anti-mouse -HRP and Chemiluminescence Substrate.

Figure 21 shows the rate of secretion of VtgCAT and  
15 Vtg-Gal in comparison with SEAP. COS-1 cells were transfected with 1  $\mu$ g of Vtg-fusion construct: control vectors in a ratio of 8:2 by liposome-mediated transfection with 5-6  $\mu$ l of Lipofectamine® reagent (Gibco-BRL) and incubated at 37°C for 5 h as described by the manufacturer.  
20 After 36 h, the medium from cells of each time point was removed and replaced with 1 ml of fresh medium at an interval of 15 min over a period of 2 h. After the last time point, which should represent 0 min, an additional 1 h incubation was employed for all transfections to avoid low  
25 reading variations. At the end of incubation, the medium was retrieved and transferred to a microcentrifuge tube. Centrifugation was carried out as 12,000 x g for 30 sec to pellet any detached cells present in the culture medium. 100  $\mu$ l of supernatant was used for ELISA. SEAP was assayed  
30 using Great Escape™ SEAP Fluorescence Detection Kit (Clontech) as described by the manufacturer. Both SSCAT and SS-Gal were assayed using CAT ELISA and  $\beta$ -Gal ELISA



(Boehringer Mannheim), respectively. For better comparison, the CAT ELISA and  $\beta$ -Gal ELISA were adapted for fluorescence using DIG Fluorescence Detection ELISA (Boehringer Mannheim). The procedures were as described by the  
 5 manufacturer. SEAP was determined using a fluorimeter (Perkin Elmer) at Ex<sub>360nm</sub> and EM<sub>449nm</sub>. VtgCAT and Vtg-Gal were detected at Ex<sub>440nm</sub> and EM<sub>550nm</sub>.

# DETAILED DESCRIPTION OF THE INVENTION

The present inventors have discovered that the portion  
 10 of the amino acid sequence of vitellogenin that directs secretion of the protein from the cell can be linked to any other polypeptide and so direct secretion of that protein from a host cell. The secretory signal sequence of the invention, herein called "SS" or "Vtgss", is found in the  
 15 amino-proximal portion of a vitellogenin protein.

The preferred SS of the invention is obtained from a piscine vitellogenin protein, preferably from the fish *Oreochromis aureus*. There is a family of vitellogenin genes in this organism, which apparently comprises four subgroups  
 20 of genes identifiable by different restriction maps of cloned cDNAs (J. L. Ding et al., *Biochem. Intl.* 20:843-852 (1990)). Melting of heteroduplexes formed between the cDNAs suggests that the overall nucleotide sequence variation among them is about 7%. The 5' end of the cDNAs show strong  
 25 homology across all four subgroups by Southern blotting (B. H. Lee et al., *Biochem. Mol. Biol. Intl.* 34:75-83 (1994)). The most preferred SS of the invention is that having the amino acid sequence MRVLVLALAVAVGDQSNLG.

The sequence MRVLVLALAVAVGDQSNLG can be modified by  
 30 amino acid replacements and by insertions or deletions from the sequence. The SS may have additional individual amino

acids or amino acid sequences inserted into the polypeptide in the middle thereof and/or at the N-terminal and/or C-terminal ends thereof so long as the SS retains the biological activities of directing secretion of a fusion  
 5 protein from a eukaryotic cell and cleavage of the secretory signal sequence from the fusion protein at a site between the G and D residues, or between any amino acids substituted for these positions. Likewise, some of the amino acids may be deleted from the SS or substituted, so long as the resulting  
 10 amino acid sequence retains those biological activities. Amino acid substitutions may also be made in the sequences so long as the polypeptide possesses the desired biological activities.

The secretion activity of the SS can be arranged by  
 15 measuring the proportion of a reporter protein secreted into the medium of cultured recombinant cells expressing SS-reporter protein fusions. The cleavage activity can be assessed by N-terminal sequencing of the secreted protein.

One or more amino acid residues within the sequence can  
 20 be substituted with another amino acid of similar polarity which acts as a functional equivalent, resulting in an altered polypeptide that retains the desired biological activities. Amino acid substitutions are preferably "conservative amino acid substitutions". "Conservative amino  
 25 acid substitutions" are substitutions of one amino acid by another amino acid wherein the charge and polarity of the two amino acids are not fundamentally different. Amino acids can be divided into the following four groups: (1) acidic amino acids, (2) neutral polar amino acids, (3) neutral non-polar  
 30 amino acids and (4) basic amino acids. Conservative amino acid changes can be made by substituting one amino acid within a group by another amino acid within the same group.

Representative amino acids within these groups include, but are not limited to, (1) acidic amino acids such as aspartic acid and glutamic acid, (2) neutral polar amino acids such as glycine, serine, threonine, cysteine, tyrosine, asparagine  
 5 and glutamine, (3) neutral non-polar amino acids such as alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and methionine, and (4) basic amino acids such as lysine, arginine and histidine.

Proline is considered to be a less favored substituting  
 10 amino acid with respect to the SS of the invention, due to its tendency to "break" alpha-helical secondary structure of peptides. Also, it is preferable to retain a basic amino acid, preferably lysine or arginine, at the second residue of the SS. Also, it is preferred that the G and D residues  
 15 constituting the cleavage site in the SS be retained; any substitution of these two amino acids is preferably A or V for the G and E for the D.

Any integral number of additions or deletions of amino acids between 0 and 4 can be made to the SS; preferably only  
 20 1 or 2 additions or deletions are made. It is preferred that the stretch of hydrophobic amino acids in the interior of the SS be kept in the range 10-15 amino acids long, preferably 11-14, most preferably 11, 12 or 13 amino acids long.

The number of substitutions that is tolerated is larger.  
 25 An important aspect of the SS is that the hydrophobic stretch in its interior portion be retained. Many of the non-polar amino acids in this portion can be substituted with other non-polar amino acids, especially those having hydrocarbon side chains, without affecting the activity of the SS.  
 30 Preferably fewer than 7 of the amino acids in the SS, more preferably fewer than 3, are substituted overall.

The DNA encoding the SS of the invention can of course vary with respect to degeneracy of the genetic code. A preferred nucleotide sequence encoding the SS of the invention is att cac atc cac cag cc atg agg gtg ctt gta cta  
5 gct ctt gct gtg gct ctc gca gtg ggg gac cag tcc aac ttg ggg.  
Also, in embodiments of the invention wherein DNA encoding a SS of the invention is joined to DNA encoding a desired protein to be expressed, the joining should be done so that the reading frame of the SS and of the desired protein are  
10 the same. The joining can be performed so that the 3' end of the DNA encoding the SS is joined directly to the 5' end of the DNA encoding the desired protein. Alternatively, the 3' end of the DNA encoding the SS can be joined to a "linker" DNA that encodes additional amino acids, which linker DNA is  
15 then joined also to the 5' end of the DNA encoding the desired protein.

In some embodiments of the invention, the desired protein is a "reporter protein" that has an easily assayed biological activity. The biological activity of the reporter  
20 protein is preferably closely correlated with the amount of the transcript encoding the reporter protein present in the cell, and in the most preferred embodiment, reflects the transcription activity of the promoter driving expression of the reporter protein. Examples of reporter proteins for  
25 which cloned DNAs and quantitative assays are known are chloramphenicol aminotransferase, green fluorescent protein or another aequorin,  $\beta$ -amylase,  $\beta$ -lactamase, luciferase, glucuronidase, alkaline phosphatase and  $\beta$ -galactosidase.

A biosensor can be made by making a construct  
30 comprising the SS and a desired protein operatively linked to a promoter sensitive to a particular chemical compound. "Operative linkage" of the promoter occurs where the

transcription of the SS-desired protein cassette is driven by the promoter in the fashion normal for the promoter. Thus, if the promoter is a constitutive one, then transcription is constant. If the promoter is chemically-  
 5 inducible or suppressible, then the transcription of the SS-desired protein cassette is similarly chemically-inducible or suppressible.

To complete the biosensor, a cell that intracellularly expresses or bears on its surface a receptor for the  
 10 compound being sensed is transformed with the construct comprising the relevant promoter operatively linked to the SS-desired protein cassette. The cell surface receptor is preferably one that is endogenous to the cell, since then one can presume that the additional proteins required for  
 15 transduction of the compound binding signal to the nucleus are present in the cell. In instances where the cell surface receptor is introduced by recombinant DNA methods, then the practitioner of ordinary skill will understand that a host cell that harbors the relevant signal transduction proteins  
 20 should be used.

Cells bearing receptors for estrogen and estrogen-like compounds ("estrogen mimics") are preferred cells for creating biosensors of the invention. The estrogen signal transduction pathway is among the better understood ones,  
 25 and several cell types that support estrogen-induced transcription of exogenous genes introduced by transformation are known (Tan et al., "Temperature-Dependence of Estrogen Binding: Importance of a Subzone in the Ligand Binding Domain of a Novel Piscine Estrogen  
 30 Receptor"; Dana et al., "Novel Estrogen Response Elements Identified by Genetic Selection in Yeast are Differentially Responsive to Estrogens and Antiestrogens in Mammalian

Cells"). Also, several cloned estrogen-responsive elements ("EREs") are known in the art (see, for example, N.S. Tan et al., *Mol. Cell. Endocrinol.* 123:149-161 (1996)).

The biosensors according to the invention allow easy  
5 assay for the presence of the relevant compound in a sample. The assay is performed by culturing cells constituting the biosensor in a medium. A sample of the medium is taken and assayed for the activity of the reporter protein encoded by the cassette to obtain a baseline level. Then the sample is  
10 introduced into the culture medium and the culture is continued. The medium is again sampled and the activity of the reporter gene measured. Changes in the activity of the reporter gene will reflect the presence of the relevant compound in the sample. Of course, alternate embodiments,  
15 such as separate, matched cultures of the biosensor cells in the presence and absence of the sample, can be envisioned. The particular media used are of course dictated by the cells used to construct the biosensor; media and methods of cell culture are generally known in the art.

20 In a similar manner, the SS of the invention can be used to make expression cassettes for any desired protein. The protein will be secreted into the medium of the culture. Use of serum-free culture media provides conditions where it is possible that the desired protein will be one of only a  
25 few, and possibly the only, polypeptide present in the culture medium. This greatly simplifies purification of the desired protein.

In other embodiments of the invention, it is desirable to produce a lipopolysaccharide-binding protein, such as  
30 Factor C of a horseshoe crab. Cloned cDNAs encoding Factor C from at least two species of horseshoe crab are known (see, U.S. Patent 5,716,834 and Muta et al., *J. Biol. Chem.*

266:6554-6561 (1991)). The lipopolysaccharide-binding protein produced by the present invention can be used in the ways described in U.S. Patents 5,712,144 and 5,716,834 and in co-pending applications 08/596,405 and 09/081,767. In

5 those embodiments of the invention directed to production of a protein for quantitative assay or purification, it is most desired that cells that do not secrete proteases are used. Preferred host cells are COS, CHO, NIH/3T3, *Drosophila* cells, especially Schneider 2 cells, piscine epithelial  
10 cells (EPC) and yeast cells, such as *S. cerevisiae* and *S. pombe* and *Pichia* spp., especially protease-deficient yeast cells.

The present invention can also be used in an assay for heterologous gene expression. In this embodiment of the  
15 invention, cells are transformed with a vector that directs the expression of the heterologous protein to be expressed. The nucleic acid encoding the heterologous protein is joined to nucleic acid encoding the SS, thereby obtaining secretion of the expressed protein into the medium upon culture of the  
20 host cells. The presence of the heterologous protein in the culture medium can then be detected, for example by assay for its biological activity, if such is known, or by an immunologic method, if an antibody that specifically binds the heterologous gene product is available. Preferred  
25 methods for immunologic detection are ELISA (in any of the various known formats) and Western blotting. Labels for detection of antibody binding are not limiting of the method, but preferably the antibody is fluorescently labeled or enzymatically labeled.

30 The SS of the invention can also be applied to "enhancer trap"-type vectors, wherein a promoterless vector carrying a reporter gene is transformed into a cell, where

it integrates at a random point in the genome in such a fashion that integration near a promoter results in expression of the reporter gene. In this embodiment, the reporter gene is made to incorporate the SS, thus expression  
5 of the reporter gene will result in secretion of the reporter protein out of the cell into the culture medium, thus simplifying screening for insertion in the vicinity of a promoter.

The SS of the invention can also be applied to  
10 expression of genes in chimeric or transgenic animals, to obtain secretion of a desired protein, especially of a therapeutic protein, into an extracellular compartment. In some embodiments, this method provides general dissemination of the protein throughout the animal. In preferred  
15 embodiments, the protein is secreted into extracellular matrix, which can thus result in local dissemination if the half-life of the protein is short or if it is made to bind to receptors on the surface of cells or to receptors in the matrix. Secretion into the extracellular matrix can also  
20 provide quite extensive dissemination if the protein has a long half-life and is able to diffuse through the matrix.

In other preferred embodiments, the protein is made to be secreted into the bloodstream, the lymphatic system or into the ducts of the breasts for secretion in milk by  
25 transformation of the appropriate cells.

**Example 1: Cloning of Vtgss in LPS-binding domain of CrFC gene (CrFCES) for expression and secretion of recombinant ES protein from *Drosophila* cells**

The *O. aureus* vitellogenin gene secretory signal  
30 (Vtgss) was fused upstream to the EcoRI-SalI cDNA fragment encoding the LPS-binding domain of *Carcinoscorpius*



*rotundicauda* Factor C CrFCES (Ding et al., 1995. *Mol. Marine Biol. & Biotechnology* 4:90-103). The construct was inserted into the pAc5/V5-His vector backbone (InVitrogen, see Fig. 1).

5 Vitellogenin is the yolk protein of the oviparous and ovoviviparous animals. It is exclusively synthesized in the liver, secreted and finally deposited in the eggs. The secretion of vitellogenin is directed by its secretory signal. The expression of the LPS-binding domain of Factor C  
10 (~333 amino acids) is challenging because it is rich in cysteine residues and requires the correct formation of 9 disulfide bonds for full biological activity. The recombinant protein (VtgssCrFCES) is synthesized using the *Drosophila* Expression System™ (InVitrogen). Stable  
15 recombinant *Drosophila* cell lines were obtained and the distribution of the protein was identified by Western blotting using chemiluminescent detection. The recombinant protein was also purified to homogeneity for N-terminal amino acid sequencing.

20 Homogeneous cleavage between Vtgss and the adjoining mature CrFCES protein was demonstrated by N-terminal amino acid sequencing of VtgCrFCES. The data show that Vtgss is cleaved at a single point (Fig. 2). The absence of multiple cleavages shows that Vtgss directs homogenous production of  
25 secreted heterologous protein.

The Western Blot shows that practically all of VtgCrFCES is secreted into the culture medium (Fig. 3). No intracellular VtgCrFCES was detected using chemiluminescent detection, which is very sensitive. The fusion of Vtgss to  
30 the LPS-binding domain resulted in its secretion whereas the native secretory signal of Factor C targets the LPS-binding domain intracellularly. The presence of VtgCrFCES in the

culture medium allows simple purification from either batch or continuous culture.

The LPS-binding properties of the secreted protein are retained as shown by plasmon resonance studies, using the BIACORE<sup>TM</sup> *in vivo* biosensor apparatus (Fig. 4). This is despite addition of 6 Vtgss-derived amino acids to the N-terminus of the CrFcES protein. Thus Vtgss is capable of driving the secretion of correctly-folded CrFcES. Functional Vtgss truncated after the aspartic acid residue that is the carboxy side of the cleavage site (see, e.g., Figure 8A) can be used to reduce the number of extra amino-terminal residues.

The expression vector employed here contains the basic features necessary for expression of recombinant proteins in heterologous cells; (1) an efficient promoter for transcription initiation; (2) enhancer elements for high level transcription; (3) mRNA processing signals such as mRNA cleavage and polyadenylation signals; (4) a polylinker containing multiple restriction endonucleases sites for insertion of foreign DNA; (5) selectable markers that can be used to select cells that have stably integrated the expression vector; and (6) plasmid backbone sequences to permit propagation in bacterial cells, etc. All eukaryotic expression systems known to date harbor several of the above-mentioned features (Kaufman, R. J., *Methods in Enzymol.* 185:487-511 (1990); Kriegler, M., *Methods in Enzymol.* 185:512-526 (1990)). Furthermore, all eukaryotes use similar mechanisms for the extracellular secretion of proteins (Barritt, G. J., ed. 1992 in "Communication within Animal Cells", pp. 42-48; Lewin, B. ed., 1994 in *Genes V*, pp. 289-293). Consequently, the rapid secretion potential conferred by Vtgss is not limited to a *Drosophila* expression

system. Other expression systems based on eukaryotic host cells (e.g., other *Drosophila* host cells; baculovirus systems; other eukaryotic host cells, including mammalian, avian, reptilian, piscine, invertebrate (see Examples 2-4) and yeast (see Example 6)) can be used with the vectors of the invention.

**Example 2: Inducible expression and secretion of the recombinant VtgssCAT and VtgssEGFP reporters from mammalian cells**

10 We have thus constructed a reporter CAT system (Figs. 5A-5G) that uses the secretory signal of the *O. aureus* vitellogenin gene (Vtgss). The excellent secretory signal provides quantitative secretion of the CAT reporter protein into the culture medium, and thus it is not necessary to  
15 prepare a cell lysate to assay for the reporter protein. An investigator is thus provided with an easy assay for CAT activity and so can retain methodology that he/she has previously established in the laboratory. This permits easy comparison with data previously obtained using a CAT  
20 reporter protein.

The psp-VtgCAT (Figs. 5D and 5E) and ERU-*psp*-VtgCAT (Fig. 5F) vectors were constructed by typical methods. The *psp*-VtgCAT has the *pSEAP*-Promoter vector backbone, but the *SEAP* gene is replaced by the recombinant VtgCAT gene. The  
25 ERU-*psp*-VtgCAT is *psp*-VtgCAT with the estrogen response unit from a *Xenopus* vitellogenin B1 gene (kindly provided by Professor W. Wahli, Switzerland) inserted upstream of the SV40 promoter. These constructs were co-transfected together with chicken estrogen receptor cDNA and *pSEAP* control DNA  
30 into various mammalian cell lines (e.g., CHO, NIH/3T3 & COS). This allows the testing of E<sub>2</sub>-inducibility of the ERU-

5 psp-VtgCAT. The secreted VtgCAT reporter protein was assayed by CAT ELISA (Boehringer Mannheim) (Fig. 6). To verify that the level of the secreted VtgCAT in the culture medium is directly proportional to changes in intracellular concentrations of VtgCAT mRNA, a Northern blot was performed under E<sub>2</sub>-stimulation over a time course (Fig. 7). The results indicate that VtgCAT is efficiently secreted from the cells, and the levels of VtgCAT in the culture medium are directly proportional to changes in intracellular concentration of VtgCAT mRNA. Furthermore, the increase in VtgCAT can be detected as early as 2 h after E<sub>2</sub>-stimulation. Importantly, the decrease in VtgCAT transcript after 24 h is also reflected by a lower amount of VtgCAT protein. This indicates that there is no delay in VtgCAT secretion. Thus, the Vtgss signal acts to immediately secrete the protein out of the mammalian cells.

10 pVtgEGFP, a green fluorescent protein reporter construct (Figs. 8A-8C) was transiently expressed in COS cells. Vtgss also efficiently secreted the EGFP fluorescent protein into the culture medium (Fig. 8D).

**Example 3: Inducible expression and secretion of recombinant CAT reporter from other mammalian cells (NIH/3T3 and CHO-B)**

25 Estrogen-inducibility of ERU-psp-VtgssCAT was also demonstrated in other mammalian cell lines. NIH/3T3 (normal mouse fibroblast cells) and CHO-B (Chinese hamster ovary cells) were transfected as described in Example 3. Three time points were assayed for VtgssCAT secretion into the culture medium, 0, 6 and 24 h post estrogen induction. Peak expression of VtgssCAT was at 24 h. NIH/3T3 and CHO-B cells exhibited a 4-fold and 5.5-fold increase in VtgssCAT (Fig.

9). The results show that the estrogen-responsiveness, production and secretion of VtgssCAT is not limited to COS-1 cells.

**Example 4: Inducible expression and secretion of recombinant CAT reporter from piscine cells**

Co-transfection of the ERU-psp-VtgCAT construct with chicken estrogen receptor cDNA into a piscine cell line (e.g., Carp Epithelial cells, EPC) also resulted in estrogen-inducible expression and secretion of the CAT reporter protein into the culture medium (Fig. 10). EPC were cultured at a low temperature of 25 °C. A 3-fold increase in VtgCAT can be detected by 24 h after estrogen-induction. The low metabolic rate of EPC likely explains the lower induction of VtgCAT compared to the levels observed in Example 3. Nonetheless, this experiment shows the efficiency of production and secretion of VtgCAT conferred by Vtgss. Furthermore, the Vtgss-directed secretion process is applicable to all eukaryotic cells; it is not limited to mammalian cells.

**Example 5: Expression of VtgCAT reporter in *S. cerevisiae* (strain DY150)**

The VtgCAT reporter was inserted downstream of the strong phosphoglycerate kinase (PGK) promoter (Fig. 11). The PGK promoter drives high constitutive expression of a heterologous protein. The plasmid provides for two selectable traits, *URA3* and *leu2-d*. Expression of VtgCAT was monitored in yeast grown in a rich YEPD medium and synthetic minimal medium (MM). From Fig. 12, it is clear that production and secretion of VtgCAT occurred as early as 24 h. The amount of VtgCAT detected in the both kinds of

-34-

culture medium is comparable. However, VtgCAT production and secretion appear to decrease by 48 h, particularly, for yeast grown in MM. By 48 h, the pH of the media has dropped to below the optimum of 5-6. This affects the growth of the transformants, and hence, production of VtgCAT. Adjusting the pH back to 5 resulted in a tremendous increase in VtgCAT in the culture media. Thus, the growth condition is important for efficient secretion of VtgCAT from yeast. We envisage that cultivation of recombinant yeast in a fermenter enables better control of growth conditions and consequently secretion of even higher amounts of VtgCAT into the culture medium. It is important to note that "secretion" in this application includes export of recombinant protein(s) into the periplasmic space, as well as through it into the culture medium, of a recombinant host cell that has a cell wall. In such instances, the "cell lysate" fraction will include proteins localized in the periplasmic compartment. In this particular example, a large proportion of the VtgCAT is found to accumulate in the periplasm. Use of wall-less mutants of yeast (or other fungi) host cells would prevent accumulation of the heterologous proteins in the periplasm. Such wall-less mutants are known in the art.

**Example 6: Inducible expression and secretion of Vtgss- $\beta$ -lactamase from bacteria**

Ampicillin binds to and inhibits a number of enzymes in the bacterial membrane that are involved in the synthesis of cell wall. The ampicillin resistance gene carried on a plasmid codes for an enzyme ( $\beta$ -lactamase) that is secreted into the periplasmic space of the bacterium, where it catalyzes hydrolysis of the  $\beta$ -lactam ring with concomitant detoxification of ampicillin. To demonstrate the

universality of Vtgss to direct secretion of recombinant proteins in bacteria, the native secretory signal of  $\beta$ -lactamase was replaced with Vtgss. The expression of this new fusion enzyme (Vtg- $\beta$ -lactamase) is under the control of  
 5 an arabinose-inducible promoter (e.g., araBAD promoter).

A  $\beta$ -lactamase gene was isolated by PCR using a blactfor forward primer which was designed to prime the start of the mature protein (i.e., to exclude the native secretory signal, see, Figures 13, 14A and 14B). Consequently, the  
 10 only means of survival for pBADVtgblactKana transformants was when Vtgss correctly directs the secretion of the "truncated"  $\beta$ -lactamase into the periplasmic space for hydrolysis of ampicillin. Sufficient functional  $\beta$ -lactamase must be secreted into the periplasm to effectively hydrolyze  
 15 ampicillin before the latter enters the cell or the host cells will die.

Expression of the  $\beta$ -lactamase in the periplasm was assayed by plating transformants on agar plates containing ampicillin and varying amount of arabinose. In the absence  
 20 of arabinose (0.2% glucose) or in the presence of only 0.0002% arabinose, no colonies are seen. This is due to the insufficient expression and/or secretion of Vtg- $\beta$ -lactamase under these conditions. When the amount of arabinose was increased (0.002 to 0.2% arabinose), a dose-dependent  
 25 expression and secretion of Vtg- $\beta$ -lactamase was observed which is reflected by the appearance of bacterial colonies on the agar plates (Fig. 15). It is envisaged that secretion of recombinant protein conferred by Vtgss will also apply for both Gram-positive and Gram-negative bacteria, since  
 30 they share similarities in their secretory mechanisms (Lewin, B., ed., 1994 in "Genes V", pp. 298-299).

The arabinose-induced vector with Vtgss is capable of directing secretion of Vtg- $\beta$ -lactamase into the periplasm as well as out of the bacteria into the culture medium (Figs. 16-18), both of which caused the hydrolysis of ampicillin, hence the survival of positive clones carrying the Vtgss signal. The expression and secretion of Vtg- $\beta$ -lactamase in this instance is strongly influenced by the bacterial growth rate and rate of transcription induction. Nonetheless, the Vtgss is a useful system for convenient screening/reporting of genetically-engineered clones harboring selectable marker(s)/enzymes (such as  $\beta$ -lactamase) to be expressed as an indicator. In the present example, the arabinose-induced growth of the positive clones in the presence of ampicillin selection is a convenient visual screen.

**Example 7: Rate of VtgCAT and Vtg-Gal Secretion in COS-1 Cells**

The construct, pVtg-Gal, which harbors a truncated  $\beta$ -galactosidase gene cloned downstream of Vtgss (Fig. 19) produced and secreted the recombinant Vtg-Gal into the medium when transfected into COS-1 cells. Western blot analysis using mouse anti- $\beta$ -galactosidase identified a ~116 kDa recombinant Vtg-Gal in the culture medium of transfected COS-1 cells (see Fig. 20). Thus, Vtgss has the potential to direct secretion of a large heterologous protein.

The amount of Vtgss-fusion protein secreted at various time intervals was determined using a standard curve created using the positive control provided by the kits. The rate of secretion was determined by the gradient of best-fit line when amount of secreted protein was plotted against time (Fig. 21). The mean rate of VtgCAT secretion was determined to be 165.778 fg/ml VtgCAT  $\beta$ -galactosidase/min  $\pm$  0.118



-37-

fg/ml/min. The mean rate of Vtg-Gal secretion was determined to be 12.14 fg/ml Vtg-Gal/ng SEAP/min  $\pm$  0.091 fg/ml/min. In comparison SEAP was secreted at a rate of 4.763 fg/ml SEAP/ng  $\beta$ -galactosidase/min  $\pm$  0.061 fg/ml/min.

5 The rate of VtgCAT and Vtg-Gal secretion were almost 3-fold higher than SEAP. This would prove very critical for experiments investigating short term or rapid transcriptions. Once again, this shows that Vtgss is capable of directing rapid secretion of recombinant proteins  
10 regardless of their size. The values for VtgCAT and SEAP secreted were normalized by  $\beta$ -galactosidase production. Similarly, the values for secreted Vtg-Gal were normalized with SEAP.

The above examples are merely illustrative of the  
15 invention and are not to be understood as limiting it. Rather, the scope of the present invention is defined by the claims following. All references of the patent and scientific periodical literature cited above are hereby incorporated in their entirety by reference by such  
20 citation.

CLAIMS:

What is claimed is:

1. An isolated nucleic acid comprising a nucleotide sequence encoding a secretory signal sequence comprising the amino acid sequence MRVLVLALAVAVGDQSNLG, or variants of said amino acid sequence that comprise conservative  
5 replacements thereof that retain the biological activities of directing secretion of a fusion protein from a cell and cleavage of the secretory signal sequence from the fusion protein.

2. An isolated nucleic acid of claim 1, wherein the nucleotide sequence encoding the secretory signal sequence is att cac atc cac cag cc atg agg gtg ctt gta cta gct ctt gct gtg gct ctc gca gtg ggg gac cag tcc aac ttg ggg.

3. An isolated nucleic acid of claim 1, wherein the cell from which secretion is directed is a eukaryotic cell.

4. An isolated nucleic acid of claim 1, wherein the cell from which secretion is directed is a prokaryotic cell.

5. An isolated nucleic acid of claim 1, wherein the secretory signal sequence is cleaved between the G and D residues in the VGDQ portion thereof.

6. An isolated nucleic acid of claim 3, wherein the secretory signal sequence is cleaved between the G and D residues in the VGDQ portion thereof.

7. An isolated nucleic acid comprising a nucleotide sequence encoding a fusion protein comprising a secretory signal sequence and a reporter protein;

wherein said secretory signal sequence comprises the amino acid sequence MRVLVLALAVAVGDQSNLG, or variants of said amino acid sequence that comprise conservative replacements thereof that retain the biological activities of directing secretion of the fusion protein from a cell and cleavage of the secretory signal sequence from the fusion protein;

wherein the reporter protein is joined to the carboxy-terminus of the secretory signal sequence, either directly or by a linking amino acid sequence.

8. An isolated nucleic acid of claim 7, wherein the nucleotide sequence encoding the secretory signal sequence is att cac atc cac cag cc atg agg gtg ctt gta cta gct ctt gct gtg gct ctc gca gtg ggg gac cag tcc aac ttg ggg.

9. The isolated nucleic acid of claim 7, wherein the reporter protein is selected from the group consisting of chloramphenicol aminotransferase, green fluorescent protein or another aequorin,  $\beta$ -amylase,  $\beta$ -lactamase, luciferase, glucuronidase, alkaline phosphatase and  $\beta$ -galactosidase.

10. The isolated nucleic acid of claim 8, wherein the reporter protein is selected from the group consisting of chloramphenicol aminotransferase, green fluorescent protein or another aequorin,  $\beta$ -amylase,  $\beta$ -lactamase, luciferase, glucuronidase, alkaline phosphatase, and  $\beta$ -galactosidase.

11. An isolated nucleic acid comprising a nucleotide sequence encoding a fusion protein comprising a secretory signal sequence and a lipopolysaccharide-binding protein;

wherein said secretory signal sequence comprises the  
5 amino acid sequence MRVLVLALAVAVGDQSNLG, or variants of said amino acid sequence that comprise conservative replacements thereof that retain the biological activities of directing secretion of the fusion protein from a cell and cleavage of the secretory signal sequence from the fusion  
10 protein;

wherein the lipopolysaccharide-binding protein is joined to the carboxy-terminus of the secretory signal sequence either directly or by a linking amino acid sequence.

12. The isolated nucleic acid of claim 11, wherein the lipopolysaccharide-binding protein is Factor C from a horseshoe crab, or a variant thereof comprising conserved amino acid replacements or insertions or deletions that  
5 retains lipopolysaccharide-binding activity.

13. The isolated nucleic acid of claim 11, wherein the nucleotide sequence encoding the secretory signal sequence is att cac atc cac cag cc atg agg gtg ctt gta cta gct ctt gct gtg gct ctc gca gtg ggg gac cag tcc aac ttg ggg.

14. The isolated nucleic acid of claim 12, wherein the nucleotide sequence encoding the secretory signal sequence is att cac atc cac cag cc atg agg gtg ctt gta cta gct ctt gct gtg gct ctc gca gtg ggg gac cag tcc aac ttg ggg.

15. A recombinant vector comprising the isolated nucleic acid of any one of claims 1-14.

16. A recombinant host cell transformed with the vector of claim 15.

17. The recombinant host cell of claim 16, wherein said cell is selected from the group consisting of a bacterial cell, a COS cell, a CHO cell, a NIH/3T3 cell, a Schneider 2 cell, a *S. cerevisiae* cell and an EPC cell.

18. An assay for heterologous gene expression comprising:

a) culturing a cell transformed with a vector comprising the isolated nucleic acid of any one of claims 7  
5 to 10 in a culture medium to obtain a reporter protein in the culture medium; and

b) assaying the biological activity of the reporter protein to determine the amount of the reporter protein present in the culture medium.

19. A method for obtaining systemic circulation of a desired protein in a transgenic or chimeric host organism comprising:

a) providing a recombinant vector comprising (i) a  
5 nucleotide sequence encoding a secretory signal sequence comprising the amino acid sequence MRVLVLALAVAVGDQSNLG, or variants of said amino acid sequence that comprise conservative replacements thereof that retain the biological activities of directing secretion of a fusion protein from a  
10 eukaryotic cell and cleavage of the secretory signal

sequence from the fusion protein, and (ii) a nucleotide sequence encoding the desired protein; wherein the nucleotide sequence encoding the secretory sequence is joined in frame to the 5' end of the nucleotide sequence  
15 encoding the desired protein; and

b) transforming a cell of the host organism with the recombinant vector *in vivo* to obtain a transgenic host organism that expresses the desired protein in an extracellular compartment, or transforming a eukaryotic cell  
20 with the recombinant vector and implanting the transformed cell in the host organism to form a chimeric host organism that expresses the desired protein in an extracellular compartment.

20. The method of claim 19, wherein the recombinant vector provided in step a) further comprises a tissue-specific promoter operatively linked to the nucleic acid nucleic acid encoding the secretory signal sequence and the  
5 desired protein to obtain tissue-specific secretion of the desired protein in step b).

21. A biosensor for detecting the presence of a compound in a sample comprising a cell that expresses a receptor that specifically binds the compound in its plasma membrane and is transformed with

5 i) a recombinant vector comprising a compound-responsive promoter that is inducible or repressible by the compound;

ii) a nucleotide sequence comprising a) a nucleotide sequence encoding a secretory signal sequence comprising the  
10 amino acid sequence MRVLVLALAVAVGDQSNLG, or variants of

said amino acid sequence that comprise conservative replacements thereof that retain the biological activities of directing secretion of a fusion protein from a cell and cleavage of the secretory signal sequence from the fusion  
15 protein, and b) a nucleotide sequence encoding a reporter protein, wherein the 5' end of the nucleotide sequence b) is joined in frame to the 3' end of the nucleotide sequence a);  
wherein the compound-responsive promoter is operatively-linked to the nucleotide sequence ii) to obtain  
20 compound-responsive secretion of the reporter protein.

22. A method for detecting the presence of a compound that binds to an estrogen receptor in a sample comprising:

- i) contacting the biosensor of claim 21 with the sample; and
- 5 ii) determining the amount of the reporter protein secreted by the cell.

23. The biosensor of claim 20, wherein the compound-responsive promoter is an estrogen-responsive element wherein estrogen induces transcription from the promoter and the cell expresses a receptor that specifically binds  
5 estrogens and estrogen-mimics.

24. The method of claim 22, wherein the compound-responsive promoter is an estrogen-responsive element wherein estrogen induces transcription from the promoter and the cell expresses a receptor that specifically binds  
5 estrogens and estrogen-mimics and the increase in the amount of the reporter protein secreted after contacting the cell with the sample is measured.

25. The biosensor of claim 21 or 23, wherein the reporter gene is selected from the group consisting of chloramphenicol aminotransferase, green fluorescent protein or another aequorin,  $\beta$ -amylase,  $\beta$ -lactamase, luciferase,  
5 glucuronidase, alkaline phosphatase and  $\beta$ -galactosidase.

26. An isolated nucleic acid comprising a nucleotide sequence encoding a fusion protein comprising a secretory signal sequence and a desired protein;

wherein said secretory signal sequence comprises the  
5 amino acid sequence MRVLVLALAVAVGDQSNLG, or variants of said amino acid sequence that comprise conservative replacements thereof that retain the biological activities of directing secretion of the fusion protein from a cell and cleavage of the secretory signal sequence from the fusion  
10 protein;

wherein the desired protein is joined to the carboxy-terminus of the secretory signal sequence, either directly or by a linking amino acid sequence.

27. A host cell comprising a vector comprising the isolated nucleic acid of claim 26.

28. A method for producing a desired protein comprising culturing a host of claim 27 under conditions wherein the desired protein is secreted from the host cell; and  
5 recovering the desired protein from the culture medium.



**ABSTRACT**

A universal secretory signal originally derived from a piscine vitellogenin (Vtg) gene is inserted into various expression vectors for driving the secretion of the recombinant protein into the culture medium. This enhances  
5 the detection, quantification and downstream scaled-up purification of a recombinant protein of interest. The secretory signal system is very versatile, being conveniently and widely applicable to an array of heterologous host cells such as bacteria, yeast, insect,  
10 piscine, and mammalian cell lines (e.g.,: COS, CHO, NIH/3T3). The said secretory system is also applicable as a reporter vector for secretion of reporter proteins/enzymes, thus, enabling the detection of the reporter proteins (e.g., CAT, GFP) in the culture medium.




Fig. 1




Fig. 2A




Fig. 2B




Fig. 3A




Fig. 3B




Fig. 4




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 5E






Fig. 5F




Fig. 5G




Fig. 6




Fig.7




Fig. 8A




Fig. 8B




Fig. 8C




Fig. 8D




Fig. 9







Fig. 10






Fig. 12




Fig. 13





Fig 14A




Fig. 14 B

Kanamycin

Amp/  
0.2% glucose

Amp/  
0.0012% ara

Amp/  
0.0012% ara

Amp/  
0.02% ara

Amp/  
0.2% ara

Fig. 15

# Growth profile of bacteria after induction




Fig. 16

# $\beta$ -lactamase in periplasmic space over time




Fig. 17



# $\beta$ -lactamase in culture medium over time




Fig. 18







Fig. 19

Figure 21




Fig. 20

# Rate of Secretion




Fig. 21

## BIRCH, STEWART, KOLASCH &amp; BIRCH, LLP

P.O. Box 747 • Falls Church, Virginia 22040-0747  
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050PLEASE NOTE:  
YOU MUST  
COMPLETE THE  
FOLLOWINGCOMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT AND DESIGN APPLICATIONS

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title:

ISOLATED NUCLEIC ACIDS ENCODING A SECRETORY SIGNAL FOR EXPRESSION AND SECRETION OF HETEROLOGOUS RECOMBINANT PROTEINSFill in Appropriate  
Information -  
For Use Without  
Specification  
Attached:

the specification of which is attached hereto, if not attached hereto,

the specification was filed on \_\_\_\_\_ as  
United States Application Number \_\_\_\_\_  
and amended on \_\_\_\_\_ (if applicable) and/or  
the specification was filed on \_\_\_\_\_ as PCT  
International Application Number \_\_\_\_\_; and was  
amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representative or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

Insert Priority  
Information:  
(if appropriate)

(Number)	(Country)	(Month/Day/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Number)	(Country)	(Month/Day/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Number)	(Country)	(Month/Day/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Number)	(Country)	(Month/Day/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

Insert Provisional  
Application(s):  
(if any)

60/106426	October 30, 1998
(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Insert Requested  
Information:  
(if appropriate)

Country	Application Number	Date of Filing (Month/Day/Year)
_____	_____	_____
_____	_____	_____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Insert Prior U.S.  
Application(s):  
(if any)

(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)

Page 1 of 2

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart  
Joseph A. Kolasch  
Bernard L. Sweeney  
Charles Gorenstein  
Leonard R. Svensson  
Andrew D. Meikle  
Joe McKinney Muncy  
John W. Bailey

(Reg. No. 21,066)  
(Reg. No. 22,463)  
(Reg. No. 24,448)  
(Reg. No. 29,271)  
(Reg. No. 30,330)  
(Reg. No. 32,868)  
(Reg. No. 32,334)  
(Reg. No. 32,881)

Terrell C. Birch  
James M. Slattery  
Michael K. Mutter  
Gerald M. Murphy, Jr.  
Terry L. Clark  
Marc S. Weiner  
Donald J. Daley  
John A. Castellano

(Reg. No. 19,332)  
(Reg. No. 28,380)  
(Reg. No. 29,680)  
(Reg. No. 28,977)  
(Reg. No. 32,644)  
(Reg. No. 32,181)  
(Reg. No. 34,313)  
(Reg. No. 35,094)

Send Correspondence to: **BIRCH, STEWART, KOLASCH & BIRCH, LLP**

P.O. Box 747 • Falls Church, Virginia 22040-0747  
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
YOU MUST  
COMPLETE  
THE  
FOLLOWING:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First  
or Sole Inventor:  
Inventor's Name of  
Inventor's Name of  
Inventor's Name of  
Inventor's Name of

Last Residence  
Inventor's Name of

Inventor's Office  
Address





Full Name of Second  
Inventor, if any:

Full Name of Third  
Inventor, if any:

Full Name of Fourth  
Inventor, if any:

Full Name of Fifth  
Inventor, if any:

Page 2 of 2  
(Revised 11-97)

GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Jeak Ling DING		26 Oct. 99
Residence (City, State & Country)	CITIZENSHIP	
Singapore, Singapore	Malaysian (Singapore P.R.)	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)		
c/o INTRO, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260		
GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Nguan Soon TAN		26 Oct. 99
Residence (City, State & Country)	CITIZENSHIP	
Singapore, Singapore	Singaporean	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)		
c/o INTRO, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260		
GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Bow HO		26 Oct. 99
Residence (City, State & Country)	CITIZENSHIP	
Singapore, Singapore	Malaysian (Singapore P.R.)	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)		
c/o INTRO, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260		
GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Toong Jia LAM		26 Oct. 99
Residence (City, State & Country)	CITIZENSHIP	
Singapore, Singapore	Singaporean	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)		
c/o INTRO, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260		
GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)	CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)		

\*DATE OF SIGNATURE